{ "labelLang" : "hun", "responseDate" : "2024-03-29 15:02", "content" : { "otype" : "JournalArticle", "mtid" : 31969539, "status" : "VALIDATED", "published" : true, "unhandledTickets" : 0, "deleted" : false, "lastRefresh" : "2023-06-05T15:49:25.488+0000", "lastModified" : "2021-11-23T15:34:12.541+0000", "created" : "2021-04-18T11:09:46.899+0000", "creator" : { "otype" : "Admin", "mtid" : 10063433, "link" : "/api/admin/10063433", "label" : "Buzási Éva (Kaposi Mór Kház 5-ös admin)", "familyName" : "Buzási", "givenName" : "Éva", "published" : true, "oldId" : 10063433, "snippet" : true }, "lastDuplumOK" : "2023-05-30T20:42:46.590+0000", "lastDuplumSearch" : "2023-05-30T20:42:46.590+0000", "adminApproved" : "2021-11-23T15:34:07.812+0000", "adminApprover" : { "otype" : "Admin", "mtid" : 10063433, "link" : "/api/admin/10063433", "label" : "Buzási Éva (Kaposi Mór Kház 5-ös admin)", "familyName" : "Buzási", "givenName" : "Éva", "published" : true, "oldId" : 10063433, "snippet" : true }, "validated" : "2021-11-23T15:34:12.549+0000", "validator" : { "otype" : "Admin", "mtid" : 10063433, "link" : "/api/admin/10063433", "label" : "Buzási Éva (Kaposi Mór Kház 5-ös admin)", "familyName" : "Buzási", "givenName" : "Éva", "published" : true, "oldId" : 10063433, "snippet" : true }, "tempLockers" : [ { "otype" : "Admin", "mtid" : 10065569, "link" : "/api/admin/10065569", "label" : "Pécsi Éva (MTMT Közp 3, admin)", "familyName" : "Pécsi", "givenName" : "Éva", "published" : true, "snippet" : true } ], "tempLocked" : "2023-06-05T15:04:38.794+0000", "core" : false, "citation" : true, "publicationPending" : false, "type" : { "otype" : "PublicationType", "mtid" : 24, "link" : "/api/publicationtype/24", "label" : "Folyóiratcikk", "code" : 24, "otypeName" : "JournalArticle", "listPosition" : 1, "published" : true, "oldId" : 24, "snippet" : true }, "subType" : { "otype" : "SubType", "mtid" : 1134514, "link" : "/api/subtype/1134514", "label" : "Összefoglaló cikk (Folyóiratcikk)", "name" : "Összefoglaló cikk", "nameEng" : "Survey paper", "docType" : { "otype" : "PublicationType", "mtid" : 24, "link" : "/api/publicationtype/24", "label" : "Folyóiratcikk", "code" : 24, "otypeName" : "JournalArticle", "listPosition" : 1, "published" : true, "oldId" : 24, "snippet" : true }, "listPosition" : 102, "published" : true, "oldId" : 1134514, "snippet" : true }, "category" : { "otype" : "Category", "mtid" : 1, "link" : "/api/category/1", "label" : "Tudományos", "published" : true, "oldId" : 1, "snippet" : true }, "languages" : [ { "otype" : "Language", "mtid" : 10002, "link" : "/api/language/10002", "label" : "Angol", "name" : "Angol", "nameEng" : "English", "published" : true, "oldId" : 2, "snippet" : true } ], "firstAuthor" : "Lane, Laura C", "authorships" : [ { "otype" : "PersonAuthorship", "mtid" : 95996974, "link" : "/api/authorship/95996974", "label" : "Lane, Laura C", "listPosition" : 1, "share" : 0.0, "first" : true, "last" : false, "corresponding" : false, "familyName" : "Lane", "givenName" : "Laura C", "authorTyped" : true, "editorTyped" : false, "otherTyped" : false, "type" : { "otype" : "AuthorshipType", "mtid" : 1, "link" : "/api/authorshiptype/1", "label" : "Szerző", "code" : 0, "published" : true, "oldId" : 0, "snippet" : true }, "published" : false, "snippet" : true }, { "otype" : "PersonAuthorship", "mtid" : 95996975, "link" : "/api/authorship/95996975", "label" : "Cheetham, Tim D", "listPosition" : 2, "share" : 0.0, "first" : false, "last" : false, "corresponding" : false, "familyName" : "Cheetham", "givenName" : "Tim D", "authorTyped" : true, "editorTyped" : false, "otherTyped" : false, "type" : { "otype" : "AuthorshipType", "mtid" : 1, "link" : "/api/authorshiptype/1", "label" : "Szerző", "code" : 0, "published" : true, "oldId" : 0, "snippet" : true }, "published" : false, "snippet" : true }, { "otype" : "PersonAuthorship", "mtid" : 95996976, "link" : "/api/authorship/95996976", "label" : "Perros, Petros", "listPosition" : 3, "share" : 0.0, "first" : false, "last" : false, "corresponding" : false, "familyName" : "Perros", "givenName" : "Petros", "authorTyped" : true, "editorTyped" : false, "otherTyped" : false, "type" : { "otype" : "AuthorshipType", "mtid" : 1, "link" : "/api/authorshiptype/1", "label" : "Szerző", "code" : 0, "published" : true, "oldId" : 0, "snippet" : true }, "published" : false, "snippet" : true }, { "otype" : "PersonAuthorship", "mtid" : 95996977, "link" : "/api/authorship/95996977", "label" : "Pearce, Simon H S", "listPosition" : 4, "share" : 0.0, "first" : false, "last" : true, "corresponding" : false, "familyName" : "Pearce", "givenName" : "Simon H S", "authorTyped" : true, "editorTyped" : false, "otherTyped" : false, "type" : { "otype" : "AuthorshipType", "mtid" : 1, "link" : "/api/authorshiptype/1", "label" : "Szerző", "code" : 0, "published" : true, "oldId" : 0, "snippet" : true }, "published" : false, "snippet" : true } ], "title" : "New Therapeutic Horizons for Graves’ Hyperthyroidism", "identifiers" : [ { "otype" : "PublicationIdentifier", "mtid" : 18665471, "link" : "/api/publicationidentifier/18665471", "label" : "DOI: 10.1210/endrev/bnaa022", "source" : { "otype" : "PlainSource", "mtid" : 6, "link" : "/api/publicationsource/6", "label" : "DOI", "type" : { "otype" : "PublicationSourceType", "mtid" : 10001, "link" : "/api/publicationsourcetype/10001", "label" : "DOI", "mayHaveOa" : true, "published" : true, "snippet" : true }, "name" : "DOI", "nameEng" : "DOI", "linkPattern" : "https://doi.org/@@@", "publiclyVisible" : true, "published" : true, "oldId" : 6, "snippet" : true }, "validState" : "IDENTICAL", "idValue" : "10.1210/endrev/bnaa022", "realUrl" : "https://doi.org/10.1210/endrev/bnaa022", "published" : false, "snippet" : true }, { "otype" : "PublicationIdentifier", "mtid" : 18665473, "link" : "/api/publicationidentifier/18665473", "label" : "WoS: 000610493100004", "source" : { "otype" : "PlainSource", "mtid" : 1, "link" : "/api/publicationsource/1", "label" : "WoS", "type" : { "otype" : "PublicationSourceType", "mtid" : 10003, "link" : "/api/publicationsourcetype/10003", "label" : "Indexelő adatbázis", "mayHaveOa" : false, "published" : true, "snippet" : true }, "name" : "WoS", "nameEng" : "WoS", "linkPattern" : "https://www.webofscience.com/wos/woscc/full-record/@@@", "publiclyVisible" : true, "published" : true, "oldId" : 1, "snippet" : true }, "validState" : "IDENTICAL", "idValue" : "000610493100004", "realUrl" : "https://www.webofscience.com/wos/woscc/full-record/000610493100004", "published" : false, "snippet" : true }, { "otype" : "PublicationIdentifier", "mtid" : 18665474, "link" : "/api/publicationidentifier/18665474", "label" : "Scopus: 85093706102", "source" : { "otype" : "PlainSource", "mtid" : 3, "link" : "/api/publicationsource/3", "label" : "Scopus", "type" : { "otype" : "PublicationSourceType", "mtid" : 10003, "link" : "/api/publicationsourcetype/10003", "label" : "Indexelő adatbázis", "mayHaveOa" : false, "published" : true, "snippet" : true }, "name" : "Scopus", "linkPattern" : "http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-@@@", "publiclyVisible" : true, "published" : true, "oldId" : 3, "snippet" : true }, "validState" : "IDENTICAL", "idValue" : "85093706102", "realUrl" : "http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-85093706102", "published" : false, "snippet" : true }, { "otype" : "PublicationIdentifier", "mtid" : 18665475, "link" : "/api/publicationidentifier/18665475", "label" : "PubMed: 32845332", "source" : { "otype" : "PlainSource", "mtid" : 17, "link" : "/api/publicationsource/17", "label" : "PubMed", "type" : { "otype" : "PublicationSourceType", "mtid" : 10003, "link" : "/api/publicationsourcetype/10003", "label" : "Indexelő adatbázis", "mayHaveOa" : false, "published" : true, "snippet" : true }, "name" : "PubMed", "nameEng" : "PubMed", "linkPattern" : "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=@@@&dopt=Abstract", "publiclyVisible" : true, "published" : true, "oldId" : 17, "snippet" : true }, "validState" : "IDENTICAL", "idValue" : "32845332", "realUrl" : "http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=32845332&dopt=Abstract", "published" : false, "snippet" : true }, { "otype" : "PublicationIdentifier", "mtid" : 18665472, "link" : "/api/publicationidentifier/18665472", "label" : "Egyéb URL: https://academic.oup.com/edrv/article/41/6/873/5897403", "source" : { "otype" : "PlainSource", "mtid" : 40, "link" : "/api/publicationsource/40", "label" : "Egyéb URL", "type" : { "otype" : "PublicationSourceType", "mtid" : 10006, "link" : "/api/publicationsourcetype/10006", "label" : "Link", "mayHaveOa" : true, "published" : true, "snippet" : true }, "name" : "Egyéb URL", "nameEng" : "Egyéb URL", "linkPattern" : "@@@", "publiclyVisible" : true, "published" : true, "oldId" : 40, "snippet" : true }, "validState" : "IDENTICAL", "idValue" : "https://academic.oup.com/edrv/article/41/6/873/5897403", "realUrl" : "https://academic.oup.com/edrv/article/41/6/873/5897403", "published" : false, "snippet" : true } ], "journal" : { "otype" : "Journal", "mtid" : 1408, "link" : "/api/journal/1408", "label" : "ENDOCRINE REVIEWS 0163-769X 1945-7189", "pIssn" : "0163-769X", "eIssn" : "1945-7189", "reviewType" : "REVIEWED", "noIF" : false, "sciIndexed" : true, "scopusIndexed" : true, "lang" : "FOREIGN", "hungarian" : false, "published" : true, "oldId" : 1408, "snippet" : true }, "volume" : "41", "issue" : "6", "firstPage" : "873", "lastPage" : "884", "firstPageOrInternalIdForSort" : "873", "pageLength" : 12, "publishedYear" : 2020, "digital" : true, "printed" : true, "collaboration" : "INTERNATIONAL", "sourceYear" : 2021, "foreignEdition" : true, "foreignLanguage" : true, "fullPublication" : true, "conferencePublication" : false, "nationalOrigin" : false, "missingAuthor" : false, "oaType" : "NONE", "oaCheckDate" : "2023-06-05", "oaFree" : false, "citationCount" : 0, "citationCountUnpublished" : 0, "citationCountWoOther" : 0, "independentCitCountWoOther" : 0, "doiCitationCount" : 0, "wosCitationCount" : 0, "scopusCitationCount" : 0, "independentCitationCount" : 0, "unhandledCitationCount" : 0, "citingPubCount" : 0, "independentCitingPubCount" : 0, "unhandledCitingPubCount" : 0, "citedPubCount" : 1, "citedCount" : 1, "ratings" : [ { "otype" : "SjrRating", "mtid" : 10796500, "link" : "/api/sjrrating/10796500", "label" : "sjr:D1 (2020) Scopus - Endocrinology ENDOCRINE REVIEWS 0163-769X 1945-7189", "listPos" : 3, "rankValue" : 0.1, "type" : "journal", "ratingType" : { "otype" : "RatingType", "mtid" : 10002, "link" : "/api/ratingtype/10002", "label" : "sjr", "code" : "sjr", "published" : true, "snippet" : true }, "subject" : { "otype" : "ClassificationExternal", "mtid" : 1310, "link" : "/api/classificationexternal/1310", "label" : "Scopus - Endocrinology", "published" : true, "oldId" : 1310, "snippet" : true }, "ranking" : "D1", "calculation" : "DIRECT", "published" : true, "snippet" : true } ], "ratingsForSort" : "D1", "references" : [ { "otype" : "Reference", "mtid" : 19909546, "link" : "/api/reference/19909546", "label" : "1. Smith 2016: Graves’ disease, N Engl J Med., 375, p. 1552, DOI: 10.1056/NEJMra1510030", "listPosition" : 1, "doi" : "10.1056/NEJMra1510030", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909547, "link" : "/api/reference/19909547", "label" : "2. Genere 2019: Current and emerging treatment strategies for Graves’ orbitopathy, Drugs., 79, p. 109, DOI: 10.1007/s40265-018-1045-9", "listPosition" : 2, "doi" : "10.1007/s40265-018-1045-9", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909548, "link" : "/api/reference/19909548", "label" : "3. Ponto 2015: Prevalence, phenotype, and psychosocial well-being in euthyroid/hypothyroid thyroid-associated orbitopathy, Thyroid., 25, p. 942, DOI: 10.1089/thy.2015.0031", "listPosition" : 3, "doi" : "10.1089/thy.2015.0031", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909549, "link" : "/api/reference/19909549", "label" : "4. ", "listPosition" : 4, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909550, "link" : "/api/reference/19909550", "label" : "5. Morshed 2012: Delineating the autoimmune mechanisms in Graves’ disease, Immunol Res., 54, p. 191, DOI: 10.1007/s12026-012-8312-8", "listPosition" : 5, "doi" : "10.1007/s12026-012-8312-8", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909551, "link" : "/api/reference/19909551", "label" : "6. Kleinau 2017: Structural-functional features of the thyrotropin receptor: a class a g-protein-coupled receptor at work, Front Endocrinol (Lausanne)., 8, p. 86, DOI: 10.3389/fendo.2017.00086", "listPosition" : 6, "doi" : "10.3389/fendo.2017.00086", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909552, "link" : "/api/reference/19909552", "label" : "7. Rapoport 2015: Evidence that TSH receptor A-subunit multimers, not monomers, drive antibody affinity maturation in graves’ disease, J Clin Endocrinol Metab., 100, p. E871, DOI: 10.1210/jc.2015-1528", "listPosition" : 7, "doi" : "10.1210/jc.2015-1528", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909553, "link" : "/api/reference/19909553", "label" : "8. LiVolsi 2018: The pathology of hyperthyroidism, Front Endocrinol (Lausanne)., 9, p. 737, DOI: 10.3389/fendo.2018.00737", "listPosition" : 8, "doi" : "10.3389/fendo.2018.00737", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909554, "link" : "/api/reference/19909554", "label" : "9. Armengol 2001: Thyroid autoimmune disease: demonstration of thyroid antigen-specific B cells and recombination-activating gene expression in chemokine-containing active intrathyroidal germinal centers, Am J Pathol., 159, p. 861, DOI: 10.1016/S0002-9440(10)61762-2", "listPosition" : 9, "doi" : "10.1016/S0002-9440(10)61762-2", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909555, "link" : "/api/reference/19909555", "label" : "10. Weetman 1984: Extrathyroidal sites of autoantibody synthesis in Graves’ disease, Clin Exp Immunol., 56, p. 330", "listPosition" : 10, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909556, "link" : "/api/reference/19909556", "label" : "11. Kautbally 2012: Greater efficacy of total thyroidectomy versus radioiodine therapy on hyperthyroidism and thyroid-stimulating immunoglobulin levels in patients with Graves’ disease previously treated with antithyroid drugs, Eur Thyroid J., 1, p. 122, DOI: 10.1159/000339473", "listPosition" : 11, "doi" : "10.1159/000339473", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909557, "link" : "/api/reference/19909557", "label" : "12. Tanda 2013: Prevalence and natural history of Graves’ orbitopathy in a large series of patients with newly diagnosed graves’ hyperthyroidism seen at a single center, J Clin Endocrinol Metab., 98, p. 1443, DOI: 10.1210/jc.2012-3873", "listPosition" : 12, "doi" : "10.1210/jc.2012-3873", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909558, "link" : "/api/reference/19909558", "label" : "13. Shen 2015: Antibody-independent functions of B cells: a focus on cytokines, Nat Rev Immunol., 15, p. 441, DOI: 10.1038/nri3857", "listPosition" : 13, "doi" : "10.1038/nri3857", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909559, "link" : "/api/reference/19909559", "label" : "14. El Fassi 2007: B lymphocyte depletion with the monoclonal antibody rituximab in Graves’ disease: a controlled pilot study, J Clin Endocrinol Metab., 92, p. 1769, DOI: 10.1210/jc.2006-2388", "listPosition" : 14, "doi" : "10.1210/jc.2006-2388", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909560, "link" : "/api/reference/19909560", "label" : "15. Heemstra 2008: Rituximab in relapsing Graves’ disease, a phase II study, Eur J Endocrinol., 159, p. 609, DOI: 10.1530/EJE-08-0084", "listPosition" : 15, "doi" : "10.1530/EJE-08-0084", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909561, "link" : "/api/reference/19909561", "label" : "16. Kahaly 2020: A novel anti-CD40 monoclonal antibody, iscalimab, for control of graves hyperthyroidism-a proof-of-concept trial, J Clin Endocrinol Metab., 105, p. dgz013, DOI: 10.1210/clinem/dgz013", "listPosition" : 16, "doi" : "10.1210/clinem/dgz013", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909562, "link" : "/api/reference/19909562", "label" : "17. Neumann 2010: A small molecule inverse agonist for the human thyroid-stimulating hormone receptor, Endocrinology., 151, p. 3454, DOI: 10.1210/en.2010-0199", "listPosition" : 17, "doi" : "10.1210/en.2010-0199", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909563, "link" : "/api/reference/19909563", "label" : "18. Neumann 2014: A selective TSH receptor antagonist inhibits stimulation of thyroid function in female mice, Endocrinology., 155, p. 310, DOI: 10.1210/en.2013-1835", "listPosition" : 18, "doi" : "10.1210/en.2013-1835", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909564, "link" : "/api/reference/19909564", "label" : "19. Latif 2016: TSH receptor signaling abrogation by a novel small molecule, Front Endocrinol (Lausanne)., 7, p. 130, DOI: 10.3389/fendo.2016.00130", "listPosition" : 19, "doi" : "10.3389/fendo.2016.00130", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909565, "link" : "/api/reference/19909565", "label" : "20. Marcinkowski 2019: A new highly thyrotropin receptor-selective small-molecule antagonist with potential for the treatment of Graves’ orbitopathy, Thyroid., 29, p. 111, DOI: 10.1089/thy.2018.0349", "listPosition" : 20, "doi" : "10.1089/thy.2018.0349", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909566, "link" : "/api/reference/19909566", "label" : "21. Furmaniak 2018: Blocking the TSH receptor with the human monoclonal autoantibody K1-70(TM) improves Graves’ ophthalmopathy and aids control of advanced follicular thyroid carcinoma-results of long-term treatment under the first in human single patient expanded use therapy, Eur Thyroid J., 7, p. Abstract P22", "listPosition" : 21, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909567, "link" : "/api/reference/19909567", "label" : "22. Pearce 2019: Antigen-specific immunotherapy with thyrotropin receptor peptides in Graves’ hyperthyroidism: a phase I study, Thyroid., 29, p. 1003, DOI: 10.1089/thy.2019.0036", "listPosition" : 22, "doi" : "10.1089/thy.2019.0036", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909568, "link" : "/api/reference/19909568", "label" : "23. Pavanello 2017: Rituximab: 13 open questions after 20years of clinical use, Cancer Treat Rev., 53, p. 38, DOI: 10.1016/j.ctrv.2016.11.015", "listPosition" : 23, "doi" : "10.1016/j.ctrv.2016.11.015", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909569, "link" : "/api/reference/19909569", "label" : "24. Cho 2017: Robust memory responses against influenza vaccination in pemphigus patients previously treated with rituximab, JCI Insight., 2, p. e93222, DOI: 10.1172/jci.insight.93222", "listPosition" : 24, "doi" : "10.1172/jci.insight.93222", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909570, "link" : "/api/reference/19909570", "label" : "25. Leandro 2013: B-cell subpopulations in humans and their differential susceptibility to depletionwith anti-CD20 monoclonal antibodies, Arthritis Res Ther., 15, p. S3, DOI: 10.1186/ar3908", "listPosition" : 25, "doi" : "10.1186/ar3908", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909571, "link" : "/api/reference/19909571", "label" : "26. Edwards 2004: Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis, N Engl J Med., 350, p. 2572, DOI: 10.1056/NEJMoa032534", "listPosition" : 26, "doi" : "10.1056/NEJMoa032534", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909572, "link" : "/api/reference/19909572", "label" : "27. Hehir 2017: Rituximab as treatment for anti-MuSK myasthenia gravis: Multicenter blinded prospective review, Neurology., 89, p. 1069, DOI: 10.1212/WNL.0000000000004341", "listPosition" : 27, "doi" : "10.1212/WNL.0000000000004341", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909573, "link" : "/api/reference/19909573", "label" : "28. Specks 2013: Efficacy of remission-induction regimens for ANCA-associated vasculitis, N Engl J Med., 369, p. 417, DOI: 10.1056/NEJMoa1213277", "listPosition" : 28, "doi" : "10.1056/NEJMoa1213277", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909574, "link" : "/api/reference/19909574", "label" : "29. Leandro 2005: B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients, Rheumatology (Oxford)., 44, p. 1542, DOI: 10.1093/rheumatology/kei080", "listPosition" : 29, "doi" : "10.1093/rheumatology/kei080", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909575, "link" : "/api/reference/19909575", "label" : "30. Hauser 2008: B-cell depletion with rituximab in relapsing-remitting multiple sclerosis, N Engl J Med., 358, p. 676, DOI: 10.1056/NEJMoa0706383", "listPosition" : 30, "doi" : "10.1056/NEJMoa0706383", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909576, "link" : "/api/reference/19909576", "label" : "31. Mitchell 2013: The effect of B cell depletion therapy on anti-TSH receptor antibodies and clinical outcome in glucocorticoid-refractory Graves’ orbitopathy, Clin Endocrinol (Oxf)., 79, p. 437, DOI: 10.1111/cen.12141", "listPosition" : 31, "doi" : "10.1111/cen.12141", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909577, "link" : "/api/reference/19909577", "label" : "32. Salvi 2007: Treatment of Graves’ disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study, Eur J Endocrinol., 156, p. 33, DOI: 10.1530/eje.1.02325", "listPosition" : 32, "doi" : "10.1530/eje.1.02325", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909578, "link" : "/api/reference/19909578", "label" : "33. Salvi 2015: Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves’ orbitopathy: a randomized controlled study, J Clin Endocrinol Metab., 100, p. 422, DOI: 10.1210/jc.2014-3014", "listPosition" : 33, "doi" : "10.1210/jc.2014-3014", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909579, "link" : "/api/reference/19909579", "label" : "34. Stan 2015: Randomized controlled trial of rituximab in patients with Graves’ orbitopathy, J Clin Endocrinol Metab., 100, p. 432, DOI: 10.1210/jc.2014-2572", "listPosition" : 34, "doi" : "10.1210/jc.2014-2572", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909580, "link" : "/api/reference/19909580", "label" : "35. Salvi 2006: Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression, Eur J Endocrinol., 154, p. 511, DOI: 10.1530/eje.1.02119", "listPosition" : 35, "doi" : "10.1530/eje.1.02119", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909581, "link" : "/api/reference/19909581", "label" : "36. Silkiss 2010: Rituximab for thyroid eye disease, Ophthalmic Plast Reconstr Surg., 26, p. 310, DOI: 10.1097/IOP.0b013e3181c4dfde", "listPosition" : 36, "doi" : "10.1097/IOP.0b013e3181c4dfde", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909582, "link" : "/api/reference/19909582", "label" : "37. Vannucchi 2010: Rituximab treatment in patients with active Graves’ orbitopathy: effects on proinflammatory and humoral immune reactions, Clin Exp Immunol., 161, p. 436, DOI: 10.1111/j.1365-2249.2010.04191.x", "listPosition" : 37, "doi" : "10.1111/j.1365-2249.2010.04191.x", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909583, "link" : "/api/reference/19909583", "label" : "38. Leandro 2006: Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis, Arthritis Rheum., 54, p. 613, DOI: 10.1002/art.21617", "listPosition" : 38, "doi" : "10.1002/art.21617", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909584, "link" : "/api/reference/19909584", "label" : "39. Salvi 2012: Small dose of rituximab for graves orbitopathy: new insights into the mechanism of action, Arch Ophthalmol., 130, p. 122, DOI: 10.1001/archopthalmol.2011.1215", "listPosition" : 39, "doi" : "10.1001/archopthalmol.2011.1215", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909585, "link" : "/api/reference/19909585", "label" : "40. El Fassi 2007: Evidence of intrathyroidal B-lymphocyte depletion after rituximab therapy in a patient with Graves’ disease, J Clin Endocrinol Metab., 92, p. 3762, DOI: 10.1210/jc.2007-1238", "listPosition" : 40, "doi" : "10.1210/jc.2007-1238", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909586, "link" : "/api/reference/19909586", "label" : "41. Chamberlain 2016: Rituximab does not reset defective early B cell tolerance checkpoints, J Clin Invest., 126, p. 282, DOI: 10.1172/JCI83840", "listPosition" : 41, "doi" : "10.1172/JCI83840", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909587, "link" : "/api/reference/19909587", "label" : "42. El Fassi 2011: Systemic adverse events following rituximab therapy in patients with Graves’ disease, J Endocrinol Invest., 34, p. e163", "listPosition" : 42, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909588, "link" : "/api/reference/19909588", "label" : "43. Berger 2018: Progressive multifocal leukoencephalopathy in rituximab-treated rheumatic diseases: a rare event, J Neurovirol., 24, p. 323, DOI: 10.1007/s13365-018-0615-7", "listPosition" : 43, "doi" : "10.1007/s13365-018-0615-7", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909589, "link" : "/api/reference/19909589", "label" : "44. Gea-Banacloche 2010: Rituximab-associated infections, Semin Hematol., 47, p. 187, DOI: 10.1053/j.seminhematol.2010.01.002", "listPosition" : 44, "doi" : "10.1053/j.seminhematol.2010.01.002", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909590, "link" : "/api/reference/19909590", "label" : "45. van Vollenhoven 2013: Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients, Ann Rheum Dis., 72, p. 1496, DOI: 10.1136/annrheumdis-2012-201956", "listPosition" : 45, "doi" : "10.1136/annrheumdis-2012-201956", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909591, "link" : "/api/reference/19909591", "label" : "46. Du 2017: Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment, Auto Immun Highlights., 8, p. 12, DOI: 10.1007/s13317-017-0100-y", "listPosition" : 46, "doi" : "10.1007/s13317-017-0100-y", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909592, "link" : "/api/reference/19909592", "label" : "47. Bar-Or 2018: Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: the MIRROR study, Neurology., 90, p. e1805, DOI: 10.1212/WNL.0000000000005516", "listPosition" : 47, "doi" : "10.1212/WNL.0000000000005516", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909593, "link" : "/api/reference/19909593", "label" : "48. Lee 2017: CD40 signaling in Graves disease is mediated through canonical and noncanonical thyroidal nuclear factor κB activation, Endocrinology., 158, p. 410, DOI: 10.1210/en.2016-1609", "listPosition" : 48, "doi" : "10.1210/en.2016-1609", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909594, "link" : "/api/reference/19909594", "label" : "49. Huber 2012: Genetically driven target tissue overexpression of CD40: a novel mechanism in autoimmune disease, J Immunol., 189, p. 3043, DOI: 10.4049/jimmunol.1200311", "listPosition" : 49, "doi" : "10.4049/jimmunol.1200311", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909595, "link" : "/api/reference/19909595", "label" : "50. Jacobson 2007: A CD40 Kozak sequence polymorphism and susceptibility to antibody-mediated autoimmune conditions: the role of CD40 tissue-specific expression, Genes Immun., 8, p. 205, DOI: 10.1038/sj.gene.6364375", "listPosition" : 50, "doi" : "10.1038/sj.gene.6364375", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909596, "link" : "/api/reference/19909596", "label" : "51. Tomer 2002: A C/T single-nucleotide polymorphism in the region of the CD40 gene is associated with Graves’ disease, Thyroid., 12, p. 1129, DOI: 10.1089/105072502321085234", "listPosition" : 51, "doi" : "10.1089/105072502321085234", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909597, "link" : "/api/reference/19909597", "label" : "52. Ban 2006: Association of a C/T single-nucleotide polymorphism in the 5’ untranslated region of the CD40 gene with Graves’ disease in Japanese, Thyroid., 16, p. 443, DOI: 10.1089/thy.2006.16.443", "listPosition" : 52, "doi" : "10.1089/thy.2006.16.443", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909598, "link" : "/api/reference/19909598", "label" : "53. Wang 2013: Genotype and phenotype predictors of relapse of graves’ disease after antithyroid drug withdrawal, Eur Thyroid J., 1, p. 251, DOI: 10.1159/000342621", "listPosition" : 53, "doi" : "10.1159/000342621", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909599, "link" : "/api/reference/19909599", "label" : "54. Jacobson 2005: A Graves’ disease-associated Kozak sequence single-nucleotide polymorphism enhances the efficiency of CD40 gene translation: a case for translational pathophysiology, Endocrinology., 146, p. 2684, DOI: 10.1210/en.2004-1617", "listPosition" : 54, "doi" : "10.1210/en.2004-1617", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909600, "link" : "/api/reference/19909600", "label" : "55. Chen 2006: Blockade of costimulation between T cells and antigen-presenting cells: an approach to suppress murine Graves’ disease induced using thyrotropin receptor-expressing adenovirus, Thyroid., 16, p. 427, DOI: 10.1089/thy.2006.16.427", "listPosition" : 55, "doi" : "10.1089/thy.2006.16.427", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909601, "link" : "/api/reference/19909601", "label" : "56. Carayanniotis 1997: Suppression of murine thyroiditis via blockade of the CD40-CD40L interaction, Immunology., 90, p. 421, DOI: 10.1111/j.1365-2567.1997.00421.x", "listPosition" : 56, "doi" : "10.1111/j.1365-2567.1997.00421.x", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909602, "link" : "/api/reference/19909602", "label" : "57. Ristov 2018: Characterization of the in vitro and in vivo properties of CFZ533, a blocking and non-depleting anti-CD40 monoclonal antibody, Am J Transplant., 18, p. 2895, DOI: 10.1111/ajt.14872", "listPosition" : 57, "doi" : "10.1111/ajt.14872", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909603, "link" : "/api/reference/19909603", "label" : "58. Farag 2018: Novel anti-CD40 monoclonal antibody CFZ533 in patients with primary sjogren syndrome: a phase iia double-blind, placebo controlled randomized trial, Oral Surg Oral Med Oral Pathol., 126, p. e203, DOI: 10.1016/j.oooo.2018.05.036", "listPosition" : 58, "doi" : "10.1016/j.oooo.2018.05.036", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909604, "link" : "/api/reference/19909604", "label" : "59. Wieczorek 2019: Blockade of CD40-CD154 pathway interactions suppresses ectopic lymphoid structures and inhibits pathology in the NOD/ShiLtJ mouse model of Sjögren’s syndrome, Ann Rheum Dis., 78, p. 974, DOI: 10.1136/annrheumdis-2018-213929", "listPosition" : 59, "doi" : "10.1136/annrheumdis-2018-213929", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909605, "link" : "/api/reference/19909605", "label" : "60. Smith 2018: Generation and characterization of a high affinity anti-human FcRn antibody, rozanolixizumab, and the effects of different molecular formats on the reduction of plasma IgG concentration, Mabs., 10, p. 1111", "listPosition" : 60, "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909606, "link" : "/api/reference/19909606", "label" : "61. Li 2005: Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases, J Clin Invest., 115, p. 3440, DOI: 10.1172/JCI24394", "listPosition" : 61, "doi" : "10.1172/JCI24394", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909607, "link" : "/api/reference/19909607", "label" : "62. Liu 2007: Amelioration of experimental autoimmune myasthenia gravis in rats by neonatal FcR blockade, J Immunol., 178, p. 5390, DOI: 10.4049/jimmunol.178.8.5390", "listPosition" : 62, "doi" : "10.4049/jimmunol.178.8.5390", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909608, "link" : "/api/reference/19909608", "label" : "63. Patel 2011: Neonatal Fc receptor blockade by Fc engineering ameliorates arthritis in a murine model, J Immunol., 187, p. 1015, DOI: 10.4049/jimmunol.1003780", "listPosition" : 63, "doi" : "10.4049/jimmunol.1003780", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909609, "link" : "/api/reference/19909609", "label" : "64. Zuercher 2019: Next-generation Fc receptor-targeting biologics for autoimmune diseases, Autoimmun Rev., 18, p. 102366, DOI: 10.1016/j.autrev.2019.102366", "listPosition" : 64, "doi" : "10.1016/j.autrev.2019.102366", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909610, "link" : "/api/reference/19909610", "label" : "65. Kiessling 2017: The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: a randomized phase 1 study, Sci Transl Med., 9, DOI: 10.1126/scitranslmed.aan1208", "listPosition" : 65, "doi" : "10.1126/scitranslmed.aan1208", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909611, "link" : "/api/reference/19909611", "label" : "66. Yu 1999: Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases, N Engl J Med., 340, p. 227, DOI: 10.1056/NEJM199901213400311", "listPosition" : 66, "doi" : "10.1056/NEJM199901213400311", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909612, "link" : "/api/reference/19909612", "label" : "67. Vaccaro 2005: Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels, Nat Biotechnol., 23, p. 1283, DOI: 10.1038/nbt1143", "listPosition" : 67, "doi" : "10.1038/nbt1143", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909613, "link" : "/api/reference/19909613", "label" : "68. Challa 2013: Autoantibody depletion ameliorates disease in murine experimental autoimmune encephalomyelitis, Mabs., 5, p. 655, DOI: 10.4161/mabs.25439", "listPosition" : 68, "doi" : "10.4161/mabs.25439", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909614, "link" : "/api/reference/19909614", "label" : "69. Ulrichts 2018: Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans, J Clin Invest., 128, p. 4372, DOI: 10.1172/JCI97911", "listPosition" : 69, "doi" : "10.1172/JCI97911", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909615, "link" : "/api/reference/19909615", "label" : "70. Howard 2019: Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis, Neurology., 92, p. e2661, DOI: 10.1212/WNL.0000000000007600", "listPosition" : 70, "doi" : "10.1212/WNL.0000000000007600", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909616, "link" : "/api/reference/19909616", "label" : "71. Newland 2020: Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia, Am J Hematol., 95, p. 178, DOI: 10.1002/ajh.25680", "listPosition" : 71, "doi" : "10.1002/ajh.25680", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909617, "link" : "/api/reference/19909617", "label" : "72. Robak 2019: Safety and efficacy of an anti-fcrn antibody, rozanolixizumab, in patients with primary immune thrombocytopenia: interim results of a phase II, multiple-dose study: S850, HemaSphere., 3, p. 379, DOI: 10.1097/01.HS9.0000561680.59520.7f", "listPosition" : 72, "doi" : "10.1097/01.HS9.0000561680.59520.7f", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909618, "link" : "/api/reference/19909618", "label" : "73. Lin 2016: Serum BAFF and thyroid autoantibodies in autoimmune thyroid disease, Clin Chim Acta., 462, p. 96, DOI: 10.1016/j.cca.2016.09.004", "listPosition" : 73, "doi" : "10.1016/j.cca.2016.09.004", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909619, "link" : "/api/reference/19909619", "label" : "74. Lane 2019: Analysis of BAFF gene polymorphisms in UK Graves’ disease patients, Clin Endocrinol (Oxf)., 90, p. 170, DOI: 10.1111/cen.13872", "listPosition" : 74, "doi" : "10.1111/cen.13872", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909620, "link" : "/api/reference/19909620", "label" : "75. Lin 2016: Analysis of associations of human BAFF gene polymorphisms with autoimmune thyroid diseases, Plos One., 11, p. e0154436, DOI: 10.1371/journal.pone.0154436", "listPosition" : 75, "doi" : "10.1371/journal.pone.0154436", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909621, "link" : "/api/reference/19909621", "label" : "76. Stohl 2012: Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus, Arthritis Rheum., 64, p. 2328, DOI: 10.1002/art.34400", "listPosition" : 76, "doi" : "10.1002/art.34400", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909622, "link" : "/api/reference/19909622", "label" : "77. Campi 2015: B cell activating factor (BAFF) and BAFF receptor expression in autoimmune and nonautoimmune thyroid diseases, Thyroid., 25, p. 1043, DOI: 10.1089/thy.2015.0029", "listPosition" : 77, "doi" : "10.1089/thy.2015.0029", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909623, "link" : "/api/reference/19909623", "label" : "78. Navarra 2011: Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial, Lancet., 377, p. 721, DOI: 10.1016/S0140-6736(10)61354-2", "listPosition" : 78, "doi" : "10.1016/S0140-6736(10)61354-2", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909624, "link" : "/api/reference/19909624", "label" : "79. Kraaij 2018: The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus, J Autoimmun., 91, p. 45, DOI: 10.1016/j.jaut.2018.03.003", "listPosition" : 79, "doi" : "10.1016/j.jaut.2018.03.003", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909625, "link" : "/api/reference/19909625", "label" : "80. Jayne 2019: Efficacy and safety of belimumab and azathioprine for maintenance of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized controlled study, Arthritis Rheumatol., 71, p. 952, DOI: 10.1002/art.40802", "listPosition" : 80, "doi" : "10.1002/art.40802", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909626, "link" : "/api/reference/19909626", "label" : "81. Marcinkowski 2019: Thyrotropin receptor: allosteric modulators illuminate intramolecular signaling mechanisms at the interface of ecto- and transmembrane domain, Mol Pharmacol., 96, p. 452, DOI: 10.1124/mol.119.116947", "listPosition" : 81, "doi" : "10.1124/mol.119.116947", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909627, "link" : "/api/reference/19909627", "label" : "82. Evans 2010: Monoclonal autoantibodies to the TSH receptor, one with stimulating activity and one with blocking activity, obtained from the same blood sample, Clin Endocrinol (Oxf)., 73, p. 404, DOI: 10.1111/j.1365-2265.2010.03831.x", "listPosition" : 82, "doi" : "10.1111/j.1365-2265.2010.03831.x", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909628, "link" : "/api/reference/19909628", "label" : "83. Furmaniak 2012: In vivo effects of a human thyroid-stimulating monoclonal autoantibody (M22) and a human thyroid-blocking autoantibody (K1-70), Auto Immun Highlights., 3, p. 19, DOI: 10.1007/s13317-011-0025-9", "listPosition" : 83, "doi" : "10.1007/s13317-011-0025-9", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909629, "link" : "/api/reference/19909629", "label" : "84. Akdis 2015: Mechanisms of allergen-specific immunotherapy and immune tolerance to allergens, World Allergy Organ J., 8, p. 17, DOI: 10.1186/s40413-015-0063-2", "listPosition" : 84, "doi" : "10.1186/s40413-015-0063-2", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909630, "link" : "/api/reference/19909630", "label" : "85. Streeter 2015: Preclinical development and first-in-human study of ATX-MS-1467 for immunotherapy of MS, Neurol Neuroimmunol Neuroinflamm., 2, p. e93, DOI: 10.1212/NXI.0000000000000093", "listPosition" : 85, "doi" : "10.1212/NXI.0000000000000093", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909631, "link" : "/api/reference/19909631", "label" : "86. Genain 1996: Late complications of immune deviation therapy in a nonhuman primate, Science., 274, p. 2054, DOI: 10.1126/science.274.5295.2054", "listPosition" : 86, "doi" : "10.1126/science.274.5295.2054", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909632, "link" : "/api/reference/19909632", "label" : "87. Alhadj Ali 2017: Metabolic and immune effects of immunotherapy with proinsulin peptide in human new-onset type 1 diabetes, Sci Transl Med., 9, DOI: 10.1126/scitranslmed.aaf7779", "listPosition" : 87, "doi" : "10.1126/scitranslmed.aaf7779", "published" : false, "snippet" : true }, { "otype" : "Reference", "mtid" : 19909633, "link" : "/api/reference/19909633", "label" : "88. Jansson 2018: Immunotherapy with apitopes blocks the immune response to TSH receptor in HLA-DR transgenic mice, Endocrinology., 159, p. 3446, DOI: 10.1210/en.2018-00306", "listPosition" : 88, "doi" : "10.1210/en.2018-00306", "published" : false, "snippet" : true } ], "hasCitationDuplums" : false, "userChangeableUntil" : "2021-07-17T11:09:55.460+0000", "directInstitutesForSort" : "", "ownerAuthorCount" : 1, "ownerInstituteCount" : 1, "directInstituteCount" : 0, "authorCount" : 4, "contributorCount" : 0, "hasQualityFactor" : true, "tempLockerIds" : [ 10065569 ], "link" : "/api/publication/31969539", "label" : "Lane Laura C et al. New Therapeutic Horizons for Graves’ Hyperthyroidism. (2020) ENDOCRINE REVIEWS 0163-769X 1945-7189 41 6 873-884", "template" : "